LH-RH analogues in the treatment of young women with early breast cancer: Long-term follow-up of a phase II study

International Journal of Oncology

Volumn 46, Issue 3, 2015, Pages 1354-1360

  Recchia, Francesco ^a,b,e   Necozione, Stefano ^c   Bratta, Massimo ^b   Rosselli, Michele ^d   Guerriero, Gabriele ^b   Rea, Silvio ^b,c  

^a Civilian Hospital   (Italy)

^b Carlo Ferri Foundation   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d Oncology Department   (Italy)

^e NONE   (Italy)

Author keywords

Adjuvant therapy; High risk premenopausal early breast cancer; LH RH analogues; Premature ovarian failure

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; EXEMESTANE; FLUOROURACIL; FOLLITROPIN; GOSERELIN; LUTEINIZING HORMONE; MELPHALAN; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB; VITAMIN D; GONADORELIN;

ADULT; ALOPECIA; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DIARRHEA; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG WITHDRAWAL; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HUMAN; INFECTION; LEUKOPENIA; LONG TERM CARE; LUTEINIZING HORMONE BLOOD LEVEL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREGNANCY; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIAL; DRUG EFFECTS; FERTILITY; MIDDLE AGED; ONSET AGE; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; PREGNANCY RATE;

ADULT; AGE OF ONSET; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; FERTILITY; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PREGNANCY; PREGNANCY RATE; PREMENOPAUSE;

EID: 84921927594     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2811     Document Type: Article

References (25)

1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet ii: 104-107, 1896.
2. Clarke MG: Ovarian ablation in breast cancer 1896-1998. Milestones along hierarchy from evidence from case report to Chochrane review. BMJ 317: 1246-1248, 1998.
3. Adjuvant chemotherapy for breast cancer. NIH consensus statement Online 5: 1-19, 1985.
4. Bines J, Oleske DM and Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14: 1718-1729, 1996.
5. Recchia F, Sica G, De Filippis S, Rosselli M and Rea S: Goserelin as ovarian proitection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs 13: 417-424, 2001.
6. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G and Rea S: Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106: 514-523, 2006.
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
8. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Ass 53: 457-481, 1958.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
10. Endogenous Hormones and Breast Cancer Collaborative Group; Key TJ, Appleby PN, Reeves GK, et al: Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 14: 1009-1019, 2013.
11. Park IH, Han HS, Lee H, et al: Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer. Ann Oncol 23: 2283-2289, 2012.
12. Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337: 956-962, 1997.
13. Toledano A, Azria D, Garaud P, et al : Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol 25: 405-410, 2007.
14. Meirow D, Biederman H, Anderson RA and Wallace WH: Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol 53: 727-739, 2010.
15. Overgaard M, Hansen PS, Overgaard J, et al: for the Danish Breast Cancer Cooperative Group 82b Trial: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. New Eng J Med 337: 949-955, 1997.
16. Huzarski T, Byrski T, Gronwald J, et al: Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 31: 3191-3196, 2013.
17. De Placido S, De Laurentiis M, De Lena M, et al: GOCSI Cooperative Group: A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. Br J Cancer 92: 467-474, 2005.
18. International Breast Cancer Study Group (IBCSG); Castiglione-Gertsch M, O'Neill A, Price KN, et al: Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 95: 1833-1846, 2003.
19. Roché H, Kerbrat P, Bonneterre J, et al: Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann Oncol 17: 1221-1227, 2006.
20. LHRH-agonists in Early Breast Cancer Overview group; Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M and Sainsbury R: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a metaanalysis of individual patient data from randomised adjuvant trials. Lancet 369: 1711-1723, 2007.
21. Turner NH, Partridge A, Sanna G, Di Leo A and Biganzoli L: Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancerpatients:the benefit remains uncertain. Ann Oncol 24: 2224-2235, 2013.
22. Del Mastro L, Ceppi M, Poggio F, et al: Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev 40: 675-683, 2014.
23. Pagani O, Regan MM, Walley BA, et al; TEXT and SOFT Investigators and the International Breast Cancer Study Group: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371: 107-118, 2014.
24. Moore HCF, Unger JM, Phillips KA, et al: Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer. ASCO Annual Meeting. Presented May 31, 2014. J Clin Oncol 32 (5s): LBA505, 2014.
25. Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR and Abeloff MD: Chemoendocrine therapy for premenopausal women with axillary lymph node positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 23: 5973-5982, 2005.